- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00598156
Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva (ACT)
April 19, 2013 updated by: Lund University Hospital
Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.
Chemotherapy and bevacizumab is given for 4 months.
Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients with metastatic colorectal cancer will be treated with standard chemotherapy according to the investigators choice.
In addition to chemotherapy, Avastin (bevacizumab) will be given during the treatment period.
After the chemotherapy is finished (after 18 weeks), maintenance therapy will be given and the patients will be randomized to treatment with either with Avastin alone or Avastin in combination with Tarceva (erlotinib).
Patients with progressive disease, or patients suitable to curative resection of metastases will be taken out of study.
Study Type
Interventional
Enrollment (Actual)
249
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark
- Vejle Hospital, Department of Oncology
-
Esbjerg, Denmark
- Esbjerg Hospital
-
Herning, Denmark
- Herning Hospital
-
Hillerod, Denmark
- Hillerod Hospital, Department of Oncology
-
Odense, Denmark
- Odense Hospital, Department of Oncology
-
Roskilde, Denmark
- Roskilde Hospital, Department of Oncology
-
-
-
-
-
Jonkoping, Sweden
- Ryhov Hospital, Department of Oncology
-
Kalmar, Sweden
- Kalmar Hospital, Department of Oncology
-
Lund, Sweden, 22185
- Lund University Hospital, Department of Oncology
-
Malmo, Sweden
- University Hospital MAS
-
Stockholm, Sweden
- Karolinska University Hospital, Department of Oncology
-
Sundsvall, Sweden
- Sundsvall Hospital, Department of Oncology
-
Umeå, Sweden
- University Hospital of Norrland, Department of Oncology
-
Uppsala, Sweden
- Akademiska Hospital, Department of Oncology
-
Vaxjo, Sweden
- Växjö Hospital, Department of Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adenocarcinoma of the colon or rectum.
- Age > 18.
- Measurable disease according to RECIST criteria.
- Expected survival more than three months.
- Adequate bone marrow, liver and kidney function.
- INR < 1.5 times upper limit.
- Adequate contraception for fertile patients.
- Signed written informed consent.
Exclusion Criteria:
- Earlier chemotherapy for metastatic colorectal cancer.
- Adjuvant treatment within 6 months.
- Surgery or significant trauma within 28 days prior to study entry.
- Planned radiotherapy against target lesions.
- CNS metastases.
- Prior malignancy within 5 years except ca in situ of cervix and basal cell carcinoma.
- Bleeding diathesis
- Uncontrolled hypertension.
- Significant cardiovascular disease.
- Treatment with anticoagulant drugs.
- Participation in other clinical trial.
- Pregnant or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
|
Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
|
|
Experimental: 2
bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
|
Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
progression-free survival
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
overall survival
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Anders Johnsson, MD PhD, Lund University Hospital, Sweden
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hansen TF, Christensen Rd, Andersen RF, Sorensen FB, Johnsson A, Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer. 2013 Sep 3;109(5):1243-51. doi: 10.1038/bjc.2013.448. Epub 2013 Aug 6.
- Johnsson A, Hagman H, Frodin JE, Berglund A, Keldsen N, Fernebro E, Sundberg J, De Pont Christensen R, Garm Spindler KL, Bergstrom D, Jakobsen A. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol. 2013 Sep;24(9):2335-41. doi: 10.1093/annonc/mdt236. Epub 2013 Jun 19.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
January 9, 2008
First Submitted That Met QC Criteria
January 17, 2008
First Posted (Estimate)
January 18, 2008
Study Record Updates
Last Update Posted (Estimate)
April 22, 2013
Last Update Submitted That Met QC Criteria
April 19, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Bevacizumab
Other Study ID Numbers
- ML19033
- EUDRACT 2006-002295-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.